Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2006 | 12-2005 | 12-2004 | 12-2003 | 12-2002 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,183 | 16,321 | -11,691 | 30,864 | 39,724 |
| Depreciation Amortization | 15,545 | 15,519 | 30,204 | 13,429 | 5,733 |
| Income taxes - deferred | -724 | -2,787 | -4,366 | 3,280 | 3,157 |
| Accounts receivable | -11,767 | -7,871 | 3,971 | -980 | -3,607 |
| Accounts payable and accrued liabilities | -6,149 | 7,500 | 846 | 2,060 | -967 |
| Other Working Capital | -12,300 | 12,698 | 9,360 | -3,980 | -12,177 |
| Other Operating Activity | 24,494 | 1,051 | 8,241 | 1,621 | 2,906 |
| Operating Cash Flow | $11,282 | $42,431 | $36,565 | $46,294 | $34,769 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16,715 | -19,462 | -23,961 | -30,964 | -17,704 |
| Net Acquisitions | -11,607 | N/A | N/A | -28,304 | N/A |
| Purchase Of Investment | -141,373 | -183,117 | -63,213 | -34,081 | -87,660 |
| Sale Of Investment | 160,646 | 174,980 | 76,268 | 41,425 | 71,191 |
| Investing Cash Flow | $-9,049 | $-27,599 | $-10,906 | $-51,924 | $-34,173 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 30,071 | N/A |
| Debt Repayment | -4,585 | -30,072 | -4,521 | -8,960 | -668 |
| Common Stock Issued | 581 | 1,323 | 1,846 | 1,135 | 1,194 |
| Common Stock Repurchased | N/A | N/A | N/A | -13,492 | -23,228 |
| Other Financing Activity | 34 | 416 | 0 | 0 | 0 |
| Financing Cash Flow | $-3,970 | $-28,333 | $-2,675 | $8,754 | $-22,702 |
| Exchange Rate Effect | 255 | -64 | N/A | N/A | N/A |
| Beginning Cash Position | 27,606 | 41,171 | 18,187 | 15,063 | 37,169 |
| End Cash Position | 26,124 | 27,606 | 41,171 | 18,187 | 15,063 |
| Net Cash Flow | $-1,482 | $-13,565 | $22,984 | $3,124 | $-22,106 |
| Free Cash Flow | |||||
| Operating Cash Flow | 11,282 | 42,431 | 36,565 | 46,294 | 34,769 |
| Capital Expenditure | -16,453 | -19,166 | -23,716 | -30,554 | -17,387 |
| Free Cash Flow | -5,171 | 23,265 | 12,849 | 15,740 | 17,382 |